Biocon Ltd is main India’s push into weight reduction medicine as patents for a number of the blockbuster drugs are set to run out.
The pharma firm has gained approval from the UK regulator for the primary generic model of liraglutide injectible, which is shedding patent safety in November.
Novo Nordisk’s weight reduction drug, bought below the model title Saxenda, is among the many first anti-obesity drugs to lose patent safety.
ALSO READ: Can weight reduction medicine like Ozempic, Wegovy deal with different ailments?
“My management crew and organisation is guaranteeing that we don’t hand over the lead place we now have now,” Biocon chief government officer (CEO) Siddharth Mittal stated in an interview, in line with Bloomberg.
He additionally stated that one other 15 peptide formulations are below growth, of which one or two medicine will search regulatory approval this yr.
Biocon has additionally filed functions earlier than the US and European regulators for liraglutide.
The corporate has not but filed for liraglutide approval in India.
Anti-obesity market
A number of pharma corporations are wanting to enter the anti-obesity market, which is predicted to the touch $100 billion by 2030.
Saxenda is claimed to be much less efficient for weight reduction than Wegovy and Ozempic, however its generic model is just the start of a jackpot that drugmakers like Biocon are awaiting.
Patents on Ozempic and Wegovy will expire within the coming years, which is able to enable cheaper copies of the remedy to flood the market.
Within the UK, Biocon will anticipate the publicly funded Nationwide Well being Providers to drift a young to launch its liraglutide injectible, stated Mittal, as per the Bloomberg report.
ALSO READ: Novo Nordisk pays $25.8 million to advertise its weight problems drug
Biocon had filed the UK software by means of its European companion Zentiva SA.
The full addressable UK market alternative for GLP-1 in diabetes and weight reduction is $425 million, in line with a March 27 assertion by Biocon.
Indian drugmakers Solar Pharmaceutical Industries, Dr. Reddy’s Laboratories, and Cipla are additionally growing their anti-obesity medicine.
Novo Nordisk, which sells its semaglutide-based tablet Rybelsus in India, is planning to introduce Wegovy and Ozempic in 2026, in line with a Reuters report in February.
Eli Lilly is conducting scientific trials within the nation for its weight-loss tablet orforglipron.
Unlock a world of Advantages! From insightful newsletters to real-time inventory monitoring, breaking information and a personalised newsfeed – it is all right here, only a click on away! Login Now!
Obtain The Mint Information App to get Each day Market Updates.
Extra
Much less
Revealed: 08 Apr 2024, 04:54 PM IST
